Hongwen Li

Dr. Hongwen Li


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2021 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
JWJingru Wang
Jingru Wang
SGShengnan Gao
Shengnan Gao
JZJingyuan Zhang
Jingyuan Zhang
CLChunxiao Li
Chunxiao Li
HLHongwen Li
Hongwen Li
JLJiangtao Lin
Jiangtao Lin
Background: Allergic asthma is a chronic airway inflammatory disease with a number of cytokines participating in its pathogenesis and progress. Interleukin (IL)-22, which is derived from lymphocytes, acts on epithelial cells and play a role in the chronic airway inflammation. However, the actual role of IL-22 in allergic asthma is still unclear. Therefore, we explored the effect of IL-22 on allergic airway inflammation and airway hyperresponsiveness (AHR) in an ovalbumin (OVA)-induced asthma mouse model. Methods: To evaluate the effect of IL-22 in an allergic asthma model, BALB/c mice were sensitized and challenged with OVA; then the recombinant mouse IL-22 was administered intranasally 24 h prior to each challenge. The IL-22 levels in lung homogenates and bronchoalveolar lavage fluid (BALF) were measured by enzyme linked immunosorbent assay, respectively. AHR was evaluated through indicators including airways resistance (Rrs), elastance (Ers) and compliance (Crs); the inflammatory cell infiltration was assessed by quantification of differential cells counts in BALF and lung tissues stained by hematoxylin and eosin (H&E); IL-22 specific receptors were determined by immunohistochemistry staining. Results: The concentration of IL-22 was significantly elevated in the OVA-induced mice compared with the control mice in lung homogenates and BALF. In the OVA-induced mouse model, IL-22 administration could significantly attenuate AHR, including Rrs, Ers and Crs, decrease the proportion of eosinophils in BALF and reduce inflammatory cell infiltration around bronchi and their concomitant vessels, compared with the OVA-induced group. In addition, the expression of IL-22RA1 and IL-10RB in the lung tissues of OVA-induced mice was significantly increased compared with the control mice, while it was dramatically decreased after the treatment with IL-22, but not completely attenuated in the IL-22-treated mice when compared with the control mice. Conclusion: Interleukin-22 could play a protective role in an OVA-induced asthma model, by suppressing the inflammatory cell infiltration around bronchi and their concomitant vessels and airway hyperresponsiveness, which might associate with the expression of its heterodimer receptors. Thus, IL-22 administration might be an effective strategy to attenuate allergic airway inflammation.

10 June 2024 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
DLDongmei Li
Dongmei Li
HJHongjuan Jiang
Hongjuan Jiang
YSYanhong Sun
Yanhong Sun
XCXiangyu Chi
Xiangyu Chi
XZXuan Zhang
Xuan Zhang
HLHongwen Li
Hongwen Li
Background: The mortality of pneumonia in older adults surpasses that of other populations, especially with the prevalence of coronavirus disease 2019 (COVID-19). Under the influence of multiple factors, a series of geriatric syndromes brought on by age is one of the main reasons for the poor prognosis of pneumonia. This study attempts to analyze the impact of geriatric syndrome on the prognosis of pneumonia. Methods: This is a prospective cross-sectional study. Patients over 65 years old with COVID-19 and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-negative community-acquired pneumonia (SN-CAP) were included in the research. General characteristics, laboratory tests, length of stay (LOS), and comprehensive geriatric assessment (CGA) were collected. Multivariate regression analysis to determine the independent predictors of the severity, mortality, and LOS of COVID-19. At the same time, the enrolled subjects were divided into three categories by clustering analysis of 10 CGA indicators, and their clinical characteristics and prognoses were analyzed. Results: A total of 792 subjects were included in the study, including 204 subjects of SN-CAP (25.8%) and 588 subjects (74.2%) of COVID-19. There was no significant difference between non-severe COVID-19 and SN-CAP regarding mortality, LOS, and CGA (P > 0.05), while severe COVID-19 is significantly higher than both (P < 0.05). The Barthel Index used to assess the activities of daily living was an independent risk factor for the severity and mortality of COVID-19 and linearly correlated with the LOS (P < 0.05). The cluster analysis based on the CGA indicators divided the geriatric pneumonia patients into three groups: Cluster 1 (n = 276), named low ability group, with the worst CGA, laboratory tests, severity, mortality, and LOS; Cluster 3 (n = 228), called high ability group with the best above indicators; Cluster 2 (n = 288), named medium ability group, falls between the two. Conclusion: The Barthel Index indicates that decreased activities of daily living are an independent risk factor for the severity, mortality, and LOS of geriatric COVID-19. Geriatric syndrome can help judge the prognosis of pneumonia in older adults.

1 July 2024 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
HJHongjuan Jiang
Hongjuan Jiang
XCXiangyu Chi
Xiangyu Chi
YSYanhong Sun
Yanhong Sun
HLHongwen Li
Hongwen Li
Background: Previous research indicated that vitamin D binding protein (VDBP) is an independent multifunctional protein that plays a vital role in acute inflammatory and tissue damage. However, its role in acute lung injury (ALI) due to coronavirus disease 2019 (COVID-19) is unclear, and studies are lacking. This study intends to investigate the difference in serum VDBP levels in COVID-19 patients with ALI or without ALI and further explore the role of VDBP in the inflammatory response of ALI through cellular models. Methods: The serum was collected from COVID-19 patients, and the concentration of serum VDBP was detected. Construct a VDBP gene-silencing plasmid and transfect it into human alveolar epithelial A549 cells. After 72 hours of lipopolysaccharide (LPS) intervention, The inflammatory factors interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) were detected, and cell counting kit-8 (CCK-8) assay was used to detect cell viability. Flow cytometry was used to detect cell apoptosis. Results: The serum concentration of VDBP was significantly higher in COVID-19 with ALI (P < 0.05). Correlation analysis indicated serum VDBP positively correlated with leukocyte (r=0.329, P = 0.002), c-reaction protein (r = 0.470, P < 0.001), serum amyloid A (r = 0.900, P < 0.001), procalcitonin (r = 0.670, P < 0.001), and interleukin 6 (r = 0.452, P < 0.001). Simultaneously, the logistic regression analysis showed that increased serum VDBP was an independent risk factor for ALI in COVID-19 patients (OR 1.003 95% CI 1.001– 1.006, P = 0.002). In human alveolar epithelial A549 cells, after LPS intervention, the inflammatory factor IL-1β and TNF-A significantly reduced in the VDBP gene silencing group compared to the negative control (NC) group (P < 0.05). The cell viability of the VDBP gene silencing group was significantly increased compared to the NC group, and the cell apoptosis rate was significantly reduced (P < 0.05). Conclusion: In COVID-19 patients, acute lung injury may lead to increased serum concentration of VDBP. VDBP plays a vital role in promoting inflammatory response and apoptosis of bronchial epithelial cells.

4 July 2024 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
DLDongmei Li
Dongmei Li
HJHongjuan Jiang
Hongjuan Jiang
YSYanhong Sun
Yanhong Sun
XCXiangyu Chi
Xiangyu Chi
XZXuan Zhang
Xuan Zhang
HLHongwen Li
Hongwen Li

8 November 2023 in Research Square
Verified
Preprint
Open access
PDF file
HJHongjuan Jiang
Hongjuan Jiang
XCXiangyu Chi
Xiangyu Chi
YSYanhong Sun
Yanhong Sun
JWJing Wang
Jing Wang
HLHongwen Li
Hongwen Li
Background Vitamin D-binding protein (VDBP) may be involved in the occurrence and development of COVID-19. This study intends to investigate the expression of VDBP in COVID-19 and to explore the role of VDBP through animal and cellular models of acute lung injury (ALI). Methods The serum of COVID-19 and common pneumonia over 65 years old in the Department of Geriatrics of the Shandong Provincial Hospital Affiliated to Shandong First Medical University were collected from 1 December 2022 to 30 July 2023. ELISA was used to detect the expression of serum VDBP. The mouse model of ALI was established by intraperitoneal injection of LPS, and the expression of VDBP in the lung tissue of ALI mice was detected by immunohistochemistry and Western blot. Construct a VDBP gene-silencing plasmid and transfect it into human alveolar epithelial A549 cells. After 72 hours of LPS intervention, collect cells and cell supernatant for testing. CCK8 detection of cell proliferation. Flow cytometry was used to detect apoptosis in cells. Results The VDBP of severe COVID-19 was higher than that of non-severe COVID-19 and common pneumonia (p < 0.05), but the VDBP was not an independent risk factor for the severity of COVID-19 (p > 0.05). Immunohistochemistry and Western blot suggest that VDBP in lung tissue of ALI mice was significant overexpression (p < 0.05). VDBP in LPS-induced injury of alveolar epithelial cells was significant overexpression (p < 0.05). The ELISA results showed that after LPS intervention, the inflammatory factor IL-1β and TNF-a was significantly reduced in the VDBP gene silencing group compared to the control group (p < 0.05). The cell proliferation ability of the VDBP gene silencing group was significantly increased compared to the control group, and the cell apoptosis rate was significantly reduced compared to the control group (p < 0.05). Conclusion The level of VDBP in severe COVID-19 was significantly increased. VDBP may play an inflammatory factor in ALI and promote apoptosis of bronchial epithelial cells.

13 August 2026 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
JZJing Zhang
Jing Zhang
HLHongwen Li
Hongwen Li
XCXiangyu Chi
Xiangyu Chi
GZGuoying Zhang
Guoying Zhang
HJHongjuan Jiang
Hongjuan Jiang
Background: Recent studies have found that VDBP gene polymorphism is closely related to the pathogenesis of some respiratory diseases. Rs7041 and rs4588 are two major single-nucleotide polymorphisms(SNPs) in the GC gene encoding VDBP. Different combinations of these variants give rise to three major haplotypic isoforms, GC*1F, GC*1S, and GC*2, which may influence pulmonary immune-inflammatory responses and immune regulation. This systematic review and meta-analysis aimed to clarify the associations between VDBP gene polymorphisms and respiratory diseases including chronic obstructive pulmonary disease(COPD), asthma, Corona Virus Disease-2019(COVID-19) and tuberculosis, so as to provide evidence for the formulation of individualized prevention and therapeutic strategies in the future. Methods: We searched the Pubmed, web of science, Wanfang, Embase and China National Knowledge Infrastructure(CNKI) to find the eligible case–control studies. Study quality was assessed using the Newcastle–Ottawa Scale (NOS). Forest plots were generated using Review Manager version 5.4, and pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Results: A total of 30 studies involving 8,844 participants were included. No significant associations were observed between the rs7041 or rs4588 polymorphism and COPD susceptibility (both P > 0.05). In the analysis of GC variants, GC*1F-related genetic models were associated with an increased risk of COPD. The ORs for GC*1F/1F versus GC*1F/1S and for GC*1F/1F versus GC*1S/1S group were 1.73 and 2.17, respectively. The OR for the GC*1F/1F homozygous comparison was 1.96, and the GC*1F allele analysis was also statistically significant ( P = 0.0003). Ethnicity-based subgroup analyses suggested that GC*1F may be primarily associated with increased COPD susceptibility in East Asian populations. In non-East Asian populations, GC*2 showed a trend toward a reduced risk of COPD, although this association did not reach statistical significance (OR = 0.52, P = 0.09). In the asthma analysis, GC*2 may be associated with an increased risk of asthma ( P ≤ 0.001). However, because relatively few studies were available for asthma, COVID-19, and tuberculosis, and substantial heterogeneity was present in some analyses, the current evidence remains insufficient to draw definitive conclusions regarding the associations between GC variants and these diseases. Conclusion: The GC*1F allele and GC*1F/1F diplotype may be associated with increased susceptibility to COPD, particularly in East Asian populations, whereas no significant associations were observed between rs7041 or rs4588 and COPD risk. GC*2 may show a potentially protective trend against COPD in non-East Asian populations but may be associated with increased asthma susceptibility. Given the limited and highly heterogeneous evidence regarding asthma, COVID-19, and tuberculosis, further high-quality studies are needed to validate these findings.